Physician profile
David Yang
NPI 1588710933
$6,398.67
in general payments reported to CMS, 2019-2025
31 companies · $879 in 2025
The $879 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $207 · 2021: $507 · 2022: $1,310 · 2023: $1,594 · 2024: $1,217 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,678 · Entertainment: $13.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,677.76 |
| Entertainment | $13.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,004.72 | 2021-2025 | |
| Pfizer INC. | $657.40 | 2019-2025 | |
| Boston Scientific Corporation | $474.85 | 2022-2025 | Watchman Access System, General - Therapies |
| Preventric Diagnostics, INC. | $461.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.63 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $404.32 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Amgen INC. | $366.59 | 2020-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $313.90 | 2020-2025 | Eliquis, Camzyos |
| Stryker Corporation | $289.09 | 2021-2024 | Prostep |
| Medtronic Vascular, INC. | $263.98 | 2019-2020 | |
| Gilead Sciences, INC. | $250.00 | 2023-2025 | Vemlidy |
| Alnylam Pharmaceuticals INC. | $176.78 | 2023-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $160.84 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $155.75 | 2020-2024 | Xarelto |
| Medtronic, INC. | $149.77 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opsens INC. | $103.02 | 2022-2023 | Optowire |
| Allergan, INC. | $97.33 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $88.19 | 2022-2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $86.58 | 2022-2024 | Verquvo |
| Amarin Pharma, INC. | $67.40 | 2022 | |
| Scpharmaceuticals INC. | $65.60 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $47.72 | 2021-2023 | |
| Inspire Medical Systems, INC. | $47.40 | 2023-2025 | Inspire |
| Cvrx, INC. | $45.87 | 2024-2025 | Barostim Neo System |
| Edwards Lifesciences Corporation | $45.34 | 2023-2024 | Sapien 3 Ultra Resilia |
| Kestra Medical Technology Services, INC. | $36.34 | 2024 | Assure Wcd |
| Abbott Laboratories | $25.00 | 2023 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $19.01 | 2022 | |
| Lantheus Medical Imaging, INC. | $17.69 | 2024 | |
| Elutia, INC. | $15.10 | 2023 | |
| Esperion Therapeutics, INC. | $14.67 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.